IDEAYA Biosciences, Inc.
IDYA
Hisse Senetlerindeki Sıralama
#4745
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Hisse Fiyatı
$32.83
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$3.17B
Değişim (1 gün)
-3.01%
Değişim (1 yıl)
12.20%
Ülke
US
Ticaret IDEAYA Biosciences, Inc. (IDYA)
Kategori
Healthcare
IDEAYA Biosciences, Inc. (IDYA) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: -92.66%
IDEAYA Biosciences, Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -92.66%'dir. 2023 yılı sonunda şirketin faaliyet marjı -574.85% idi.
IDEAYA Biosciences, Inc. için 2017 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | -92.66% | -98.02% |
| 2024 | -4,671.07% | 712.57% |
| 2023 | -574.85% | 368.42% |
| 2022 | -122.72% | -31.79% |
| 2021 | -179.91% | -0.55% |
| 2020 | -180.90% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 38.59% | -100.42% |
US
|
|
| -149.01% | -98.39% |
US
|
|
| 25.57% | -100.28% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.31% |
NL
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.